Over several millennia, substances have been applied to the skin for treatment of pain. Some ingredients are in current use; others have been discontinued.
Introduction
Over several millennia, substances have been applied externally for painful conditions but with variable success. In modern times, the mode of action of these ancient remedies has become clearer. Our Neolithic ancestors most probably used herbal remedies but records only appeared with the advent of cuneiform writing on clay tablets by the Sumerians (Third dynasty of Ur, c.3100 BCE) [1, 2] , and later by the Egyptians writing on papyrus (Kahun c.1900 BCE and Ebers papyri c.1600 BCE). [3, 4] Pharmacopoeias of "bush medicines", including environment on nociceptive signalling, both under normal conditions and in inflammatory states and neuropathic pain. We also suggest possible mechanisms of analgesia for topically applied drugs.
Illustration: Normal Human Skin
Propagation of nociception: Nociceptive sensations are detected by slowlyconducting unmyelinated C-fibres and faster-conducting myelinated A-fibres, ranging in size from thinly myelinated A-delta fibres through to thicker, more heavily myelinated A-beta fibres. [15] The faster-conducting A-fibres lose their myelin sheath in the dermis, terminating as free nerve endings. [16] These nerve endings are exquisitely sensitive to chemical and thermal disturbances in the surrounding extracellular fluid. The subsequent propagation of neural impulses involves sequential opening of voltage-gated ion channels that permit passage of sodium, potassium, chloride and calcium through the neural membrane. In addition, many other ligand-gated channels regulate neural excitability (such as acid-sensing ion channels, transient receptor potential channels, and hyperpolarization-activated cyclic nucleotide-gated channels). [17] These mechanisms make neurons particularly sensitive to minor perturbations in their local environment and also provide many targets for topical drug manipulation.
The inflammatory milieu: After injury to the skin, sensory transduction and signalling is modulated by a plethora of receptors that respond to substances released from the bloodstream, from injured tissue, from resident cells such as fibroblasts, keratinocytes, Langerhans cells and mast cells, and from immune cells recruited to the site of injury. Together, these substances produce a milieu containing, among other ingredients, hydrogen ions, prostaglandins, cytokines, growth factors, noradrenaline, glutamate, bradykinin, serotonin, histamine and adenosine. [18] This inflammatory milieu can both directly activate and sensitize nerve endings to stimulation by acting on ion channels (for example hydrogen ions that operate on acid-sensing ion channels) or by altering second-messenger systems (by acting on G-protein-coupled metabotropic receptors) such as α-adrenoceptors). Externally applied topical drugs that modify this milieu or its targets can therefore act directly to reduce pain and inflammation.
Signal transduction: Sensory afferents interact with cutaneous cells that not only provide physical and trophic support but also contribute to signal transduction.
For example, keratinocytes produce many of the receptors and transmitters expressed by neurons and, by this means, can communicate with neurons in a paracrine manner. [19, 20] This is important after nerve and tissue injury. For example, after limb fracture, neuropeptides and noradrenaline released from nerve terminals in the skin activate receptors on the surface of keratinocytes which, in turn, secrete high levels of inflammatory cytokines and nerve growth factor. [21, 22] Although many receptors exert excitatory effects on neural activity, others inhibit neural excitability and discharge (for example, μ-opioid receptors). [29] Under normal conditions, the opioid receptors are separated from agents in the extracellular fluid by the perineurium, an impermeable sheath with tight cellular junctions that enclose bundles of nerve fibres. This sheath, however, becomes porous during inflammation, thereby increasing access to protected receptors for endogenous and topically applied opioids. 
Penetrating the Stratum Corneum
The stratum corneum, the outermost layer of the skin, provides a barrier to noxious chemicals, potential infective agents, physical insults and solar radiation from the outside world that is protective for the organism. The layer protects against water loss but also presents a physical barrier to the ingress of topical and transdermal drugs. The stratum consists of multiple layers of dead hydrated corneocytes arranged in interdigitating layers that are surrounded by a lipid matrix comprising approximately 20% by volume.
[40] The microanatomy has been described as a "brick-and-mortar" structure. There can be irritant and allergic contact dermatitis or contact urticarial. Patch testing is used to ascertain the culprit allergen. [57] At this point, the distinction between topical and transdermal should be emphasised. There are several effective transdermal preparations such as transdermal fentanyl and buprenorphine, whereby the active ingredient gains access to the systemic circulation but by the transdermal route. Topical applications, however, such as the application of a lidocaine patch for post herpetic neuralgia, reduce nociception by local skin mechanisms but achieve minimal systemic levels. Although neuropathic pain states can be improved by achieving systemic levels of lidocaine, this is not the main aim of this topical application.
Historical Use of Topical Drugs
There have been a number of reviews of the use of topical agents, in particular in the management of neuropathic pain. 
Menthol:
The use of menthol stretches back into antiquity. It is a naturally occurring plant extract from several members of the plant genus Mentha (Mint) [63] but has been chemically synthesised in modern times. Menthol features in the Ebers papyrus (1550 BCE) as a remedy for stomach ailments [4] and there are claims of its cultivation for medicinal use in Japan over 2000 years ago. [63] Known in ancient Greece, the herb is named after the mythical beauty Minthe.
The pungent sweet smelling mint was used in hospitality such as the fermented barley drink called the kykeon and in funerary rites. [64] Menthol is also included amongst a number of valuable herbs in the biblical indictment of the Pharisees (Luke 11:42). Peppermint appears in the London Pharmacopoeia in 1721 and menthol, the active ingredient, was first isolated as a compound by the Dutch botanist Gambius in 1771. [65] Menthol (also known as mint camphor) is experiencing a renaissance as a topical analgesic agent. As well as providing a subjective cooling effect, it acts as a weak opioid agonist and weak sodium channel blocker. [66, 67] It is used in dermatology as an antipruritic agent, as a food additive in chewing gum and to flavour toothpaste and cigarette smoke. Menthol is a cyclic terpene alcohol acting on the transient receptor potential melastatin 8 receptor (TRPM8), a low temperature sensing receptor in the skin and mucosa, (8-28°C) [68, 69] where it imparts a cool sensation. Capsaicin, in contradistinction, was the first of the transient receptor potential family to be identified. Menthol has several desirable qualities as well as its actions as a topical antipruritic agent, including antibacterial and antifungal activity. [70] It has been shown to enhance penetration of the stratum corneum in both animal and human models [71] possibly through disruption of the lipid layer of the stratum corneum. [72] Topical menthol has analgesic actions that make it a beneficial inclusion in overthe-counter pain relief applications. In low concentrations (<1%) menthol depresses cutaneous nociception and perhaps even desensitises nociceptive C fibres. [73] In high concentrations (>30% menthol can act as an irritant. [74, 75] As menthol acts on voltage-gated channels in neuronal structures, it also has a weak local anaesthetic effect. [76, 77] There are many possible uses for this topical agent, discussed in depth elsewhere. [78] [79] [80] [81] Other substance acting on TRPM8 receptors include eucalyptol and the potent synthetic Icilin. Other capsaicinoids known to antiquity include euphorbium whose active ingredient is the potent capsaicinoid resinifratoxin, extracted from the latex of Euphorbia resinifera. [85] The physician Euphorbius may have used resinifratoxin-containing salves to treat the arthritic pains of the Emperor Augustus 63 BCE -14 CE, but it was probably in use well before this time. [85] Previously used as an emetic and violent purgative, euphorbium has been employed as a rubefacient for painful joints. [86, 87] Capsaicin activates the transient receptor potential vanilloid receptor (TRPV1), an excitatory ion channel which is also activated by higher temperatures >43°C and is sensed as being hot.
[24] Capsaicin has been extensively studied as a topical agent for the past three decades. As a low concentration, 0.025-0.075%, over-the-counter preparation (Zostrix), capsaicin has been prescribed for a number of conditions including post herpetic neuralgia. More recently it has also been marketed as an 8% patch (Qutenza) with effects lasting many weeks. [89] As a TRPV1 agonist, capsaicin induces a refractory period in nerve terminals expressing TRPV1 and in higher concentrations causes long term neuronal "defunctionalisation". [90, 91] A single application of capsaicin 8% to the skin can diminish skin hypersensitivity in neuropathic pain states for periods as long as three months, reducing the issue of poor patient compliance with the weaker preparations that require multiple applications. [89, 92] The application of the 8% patch can be intensely painful and is often applied under local anaesthesia.
Targeting TRP channels on nociceptor neurons in the skin is an attractive strategy for pain control as it can modify the peripheral pain pathway. [93] The use of capsaicin preparations as a topical application for neuropathic pain states such as post herpetic neuralgia has been the subject of several Cochrane reviews of the supporting evidence. The author's concluded that repeated application of low dose (0.075%) capsaicin was without meaningful effect beyond placebo and that prior studies had not convincingly demonstrated efficacy. The use of low dose topical capsaicin commonly caused skin irritation leading to withdrawal. [94] The use of high dose capsaicin for neuropathic pain states including post herpetic neuralgia and HIV-neuropathy provided good relief of pain for about one patient in eight (NNT=8.8). It was also concluded that high dose capsaicin was probably less effective than gabapentin or pregabalin. [95] Opioids: Opium obtained from Papaver somniferum was well known to the ancients and most probably was cultivated by the Sumerians (c. 3000 BCE) [96] and ancient Egyptians. Of particular historical interest is the use of transdermal patches of opioid in ancient Greece. Olympic victor's dark ointment (OVDO) mentioned by Galen (c. 129-200 CE), was an opium-based patch that was applied to the skin of athletes. It dried rapidly to cover a localised area and recent measurements of the transdermal transfer of morphine indicate a transfer comparable to 25% of modern transdermal patches. [97, 98] 
Facit ad maximos Dolores -useful for extreme pain
Nam ftatim liberat -providing relief immediately. [97] Perhaps this was an early indicator for a more recent and disgraceful practice in sport.
The modern contemporary use of opioids as topical agents is somewhat marginal and is mainly confined to the management of skin and corneal ulceration, having some local anti-inflammatory actions. [99, 100] The increased expression of opioid receptors on nociceptors in inflammatory pain states provides a logical target for topically applied opioids. There are indications that topically applied opioids can ameliorate the pain of skin ulcers and post radiation mucositis [99, [101] [102] [103] , but the numbers in various clinical trials have been low and further evidence is needed. Their usage is perhaps best seen in the palliative care field where they can relieve inflammatory pain without significant systemic side effects. [99] Topically applied morphine can be applied in gels and oral rinses prepared by pharmacies over a range from 0.1-2% concentration. [104, 105] Other opioids employed in topical applications include methadone [106] , fentanyl [100] , and oxycodone. [107] Mandragora: Employed as a topical analgesic agent and central sedative that is no longer used due to its toxic effects, mandragora (mandrake) has an ancient and fascinating history. Mandragora officinarum is native to the eastern Mediterranean and contains the active ingredients scopolamine and atropine. [108] It has even been termed the "Anesthetic of the Ancients". [109] It is mentioned in the Ebers papyrus as a sedative [4] and features in several hieroglyphic inscriptions. [109] Hannibal (247-182 BCE) used it to drug his opponents during the Battle of Carthage (200BCE). [110] Mentioned in the Bible, Genesis 30:14-24, mandrake subsequently achieved a reputation amongst medieval Christians for enhancing fertility. It was advocated in the writings of Flavius Josephus (c. 37-101) that a dog be employed to pull out the root, thus avoiding any lethal effects on humans from hearing the scream of the mandrake plant as it was pulled from the ground. [110] Mandrake also had demonic associations and was even used in the indictment of Joan of Arc in 1431 CE. [111] The use of mandrake most probably produced sufficient topical analgesia and sedation for the physician Hua Tuo (110-207 CE) to debride an arrow wound in General Guan Yu after the battle of Fan city but allowing him to continue playing chess, talk and laugh as if nothing had happened. [4] More recently, it featured in several of Shakespeare's works, such as Cleopatra, act 1, scene v: "Give me to drink Mandragora-that I might sleep out this great gap of time. My Antony is away." Mandragora was mixed with plant extracts such as opium and henbane (Hyoscyamus niger, another tropane alkaloid which can also be applied topically for "obstinate rheumatic pains"), to produce sedation for surgical procedures. It was evaporated into a sea sponge and the preparation known as Spongia somnifera was employed extensively until its use faded with the advent of general anaesthesia in the nineteen century CE. [109, 112] The potency and toxicity of this plant extract varied considerably depending on its mode of extraction. With no attempt at purification or precise dosing, Spongia somnifera could cause death from respiratory and circulatory depression. [113] Cocaine: Topical local anaesthetic agents currently play a significant part in treating some neuropathic pain conditions. Cocaine derived from coca leaves, Erythroxylum coca was first used as a topical local anaesthetic agent on the cornea of a frog and then a human by Karl Koller in 1884, after discussions with his friend Sigmund Freud, who was interested in cocaine for its effects on his patient's mood. [114] The origins of coca are ancient, however, dating back to the pre-Moche period (100-750 CE) in Peru and the Eastern Andes. The coca leaf was chewed or used to make tea to combat fatigue and altitude sickness. Traces of coca have been found in mummified human cadavers dating back 3000 years [115] and probably millennia before this. The French naturalist Joseph de Jussieu Local anaesthetic agents have become one of the mainstays of modern surgery.
Topical local anaesthetic agents are also finding a place in the management of some pain states, in particular neuropathic pain. The use of a 5% lidocaine patch to treat neuropathic pain states, especially post herpetic neuralgia, has received particular attention and is the subject of several reviews. [117] [118] [119] The use of a lidocaine patch has also been the subject of a 2008 Cochrane review, which concluded that three studies into its efficacy had sufficient scientific rigour to be included but provided insufficient evidence to support its use as a first-line treatment of post herpetic neuralgia. [120] More recent reviews would suggest otherwise. For example, a review by Wolff et al. concluded that a 5% lidocaine topical patch is more effective than capsaicin and pregabalin. [119] Lidocaine has also been used as a topical spray for dressing changes, for pain associated with peripheral blood flow disorders, and post herpetic neuralgia. [121] [122] [123] Safety issues have been considered in a 2002 pharmacokinetic study that considered the 5% lidocaine patch to be safe, only causing mild skin erythema and low plasma lidocaine levels [124] , but a single case report has concluded that lidocaine toxicity is possible when multiple forms of topical application are used. [125] Topical non-steroidal anti-inflammatory drugs (NSAIDs): Extracts from willow trees and other salicylate containing plants also have their origins in antiquity, possibly dating back to the Sumerians and ancient Egyptians in the treatment of fevers. The active ingredient, acetylsalicylic acid (aspirin) was synthesised by the Bayer Company in 1897. [126] Salicylates are largely administered orally but there has been some topical use of aspirin containing solutions of chloroform or ether in the treatment of post herpetic neuralgia. [127] Modern NSAID use commenced with the introduction of indomethacin in 1962. [128] Significant gastrointestinal adverse effects from the oral formulations of NSAIDs have been encountered and in an effort to reduce these effects, various topical preparations of NSAIDs have been developed. In a recent comprehensive review of these topical preparations, it was concluded that topical NSAIDs were superior to placebo and had similar outcomes to oral NSAIDs in the treatment of both acute and chronic musculoskeletal injuries. [129] Gastrointestinal side effects were less with the topical group but minor skin reactions were more frequent. Several formulations, discussion concerning penetration enhancers and guidelines for use have been published regarding this group of topical agents. [126, [130] [131] [132] Topical versus oral NSAIDs can be particularly advantageous in the elderly and have been recommended as a firstline treatment for osteoarthritis in this age group. [133] Topical Agents of the Modern Era: amitriptyline, clonidine and ketamine: Amitriptyline, a tricyclic antidepressant, has a number of actions including its ability to inhibit the reuptake of noradrenaline and serotonin. It has been shown to block various voltage gated ion channels including Na + , K + and Ca ++ [134, 135] and several receptors including α2 adrenoceptor, cholinergic, NMDA and histamine [134] [135] [136] pointing to a use as a topical agent with peripheral nerve fibre effects. [137] Although not effective in every trial [138] , amitriptyline at concentrations between 2-10%, along with some other antidepressant agents has been successfully used as a topical agent in a number of neuropathic pain states including complex regional pain syndrome (CRPS), multiple sclerosis and vulvodynia. [139] [140] [141] Amitriptyline has been employed as a sole agent or in combination with other topical agents such as ketamine and baclofen. [142] [143] [144] [145] [146] [147] Although the topical application of antidepressant drugs can reduce their unwanted central side effects, this form of administration can occasionally lead to adverse toxicity. [148] Clonidine is an α2-adrenergic receptor agonist used in the treatment of hypertension. Side effects that include somnolence and hypotension have limited its use in treating neuropathic pain states. It has, however, been found to be antinociceptive if applied to the skin and successfully used in the reduction of hyperalgesia in patients with sympathetically maintained pain [149] and painful diabetic neuropathy. [150] Blood levels of clonidine in this later RCT were below the level of detection suggesting that the effects of this topical agent were peripherally mediated and probably a direct effect on epidermal nociceptors.
Typically, it is applied as a patch (30mcg/cm 2 /day) or as a 0.1-0.2% solution.
Ketamine, which blocks glutamate N-methyl-D-aspartate (NMDA) receptors on peripheral nerve fibres, can reduce nociceptive transmission. [151] It has been studied as a topical analgesic agent and has been the subject of many trials, case reports and reviews. [152] [153] [154] It can be used as a gel or cream with relative safety and apparent efficacy mainly for localised neuropathic pain states at concentrations up to 20%. [153] There have also been a number of reports of its use in combination with other agents such as amitriptyline, baclofen and gabapentin but with mixed results. [141, 142, 147] Long-term effects on the urinary tract [155] may be circumvented by the use of topically applied ketamine, which results in low plasma levels of the drug. [156] Nevertheless, as with some other topical drugs, inappropriate or excessive use can lead to significant toxicity. [157] Combinations of drugs for topical application can be used for treatment of some 
Conclusion and Future Perspectives
A number of substances have been applied to the skin and mucosa for painful conditions over thousands of years but without any understanding of their pharmacological actions. The inevitable toxic effects of some substances have led to their withdrawal from use. Others seen to have beneficial effects continue to be applied to this day, but with considerable refinement in their use and understanding of the mechanisms involved. As the knowledge of peripheral pain pathways has increased, so has the tailoring of drugs to act on these mechanisms of nociception. After penetration of the skin they are able to act directly on the initiating factors that lead to pain. Most advantageously, the use of topical drugs has reduced the adverse effects of many of these agents that are also administered systemically. This can be of great benefit to the frail and elderly.
The future for the topical application of drugs is bright. In addition to improved targeting of specific pain mechanisms with new drugs or different formulations of existing ones, enhanced penetration agents will improve delivery of these agents. "Topicals" prepared in laminar flow facilities will allow application to areas of broken skin or mucosa without encouraging infection. Alternative routes for topical applications of drugs will be developed including the rectal mucosa, vulva and the oropharynx. Lastly, as best practice for topical drug application becomes clearer from a pharmacological perspective, so will the selection of suitable patients and pain states that are likely to respond.
Executive Summary:
• The topical application of drugs that act locally in the skin provides an attractive strategy for treating pain, reducing the potential systemic side effects of oral or parenteral administration.
• Some agents used since antiquity have been discontinued but others are used to this day.
• Mechanisms of action include effects on skin neural networks and inflammatory processes.
• The stratum corneum layer of the skin presents a significant barrier to the absorption of drugs. Penetration enhancers have evolved that improve this absorption.
• Menthol, used in ancient Egypt, is experiencing a renaissance. Acting on the TRPM8 receptor, it imparts a cool sensation to the skin and mucosa.
• Capsaicin, acting on the TRPV1 receptor, also has an ancient lineage being derived from chilli peppers. It imparts a sensation of heat to the skin and mucosa.
• Opioids, described for topical use for athletes in ancient Greece, have more recently been employed in the treatment of painful skin and corneal ulceration.
• Mandragora (Mandrake) is a topical plant extract with a long history of use that has been discontinued due to its unpredictable toxicity.
• Local anesthetic agents discovered in the nineteenth century, have their origin in cocaine from the Americas. The 5% lidocaine patch has some utility in treating neuropathic pain states such as post herpetic neuralgia.
• The use of topical NSAIDS follows in the footsteps of the application salicylate containing plants by ancient Sumerians and Egyptians. Topically applied NSAIDs show efficacy in the treatment of painful musculoskeletal structures comparable to oral ingestion but without the gastro-intestinal side effects.
• Topical amitriptyline, clonidine and ketamine are examples of modern topical agents, employed principally for neuropathic pain, that are supported by a significant literature.
• The future for topical drugs is encouraging, as the mechanisms of pain have become better understood. 
